MAPT and corticobasal degeneration disorder: The BIIB092 investigation in progressive supranuclear palsy (PASSPORT) was evaluated in a TauBasket trial, which included patients with corticobasal degeneration, frontotemporal dementia (FTLD), traumatic encephalopathy syndrome (TES), symptomatic MAPT (sMAPT) mutation carriers, and progressive nonfluent aphasia (ALZFORUM, 2019).